Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic disease that leads to joint destruction. During the last decade, the therapy of RA has been principally based on biological drugs. Although the efficacy of biological therapy has been established, patients demonstrated a high heterogeneity in clinical response...
Main Authors: | Giovanni Pallio, Federica Mannino, Natasha Irrera, Ali H. Eid, Francesco Squadrito, Alessandra Bitto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/9/1203 |
Similar Items
-
Study on Tumor Necrosis Factor-α· Gene Polymorphism in Rheumatoid Arthritis
by: Kim Kyung-Un, et al.
Published: (2007-06-01) -
Biological agents in monotherapy for the treatment of rheumatoid arthritis
by: Cem Gabay, et al.
Published: (2014-04-01) -
The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis
by: Madha Mohammed Sheet, et al.
Published: (2014-06-01) -
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
by: Yen-Ju Lin, et al.
Published: (2020-04-01) -
The Effect of Oral Administration of Silymarin on Serum Levels of Tumor Necrosis Factor-α and Interleukin-1ß in Patients with Rheumatoid Arthritis
by: Mehrdad Shavandi, et al.
Published: (2022-12-01)